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Abstract
Introduction: People born preterm at very low birth weight (VLBW,#1500g) have higher rates of risk factors for adult-onset
diseases, including cardiovascular diseases and type 2 diabetes. These risks may be mediated through epigenetic
modification of genes that are critical to normal growth and development.
Methods: We measured the methylation level of an imprinted insulin-like-growth-factor 2 (IGF2) locus (IGF2/H19) in young
adults born preterm at VLBW and in their peers born at term. We studied 158 VLBW and 161 control subjects aged 18 to 27
years from the Helsinki Study of Very Low Birth Weight Adults. Methylation fraction at two IGF2 differentially methylated
regions (DMRs) – IGF2 antisense transcript (IGF2AS, also known as IGF2 DMR0) and last exon of IGF2 (IGF2_05, also known as
IGF2 DMR2) – were measured with Sequenom Epityper. We used linear regression and adjustment for covariates to compare
methylation fractions at these DMRs between VLBW and control subjects.
Results: At one IGF2AS CpG site, methylation was significantly lower in VLBW than in control subjects, mean difference
20.017 (95% CI; 20.028, 20.005), P = 0.004. Methylation at IGF2_05 was not different between the groups.
Conclusions: Methylation of IGF2AS is altered 20 years after preterm birth at VLBW. Altered methylation may be a
mechanism of later increased disease risk but more data are needed to indicate causality.
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Introduction
It has been hypothesized that many complex adult chronic
diseases originate from conditions encountered in utero and in early
life. This was first perceived in people born at term with a lower
birth weight who have higher rates of many adult-onset diseases
(cardiovascular diseases and type 2 diabetes) or their risk factors
[1–4]. Also individuals that were in utero exposed to caloric
deprivation during the Dutch and Biafran famines have been
shown to be in excess risk of several common chronic diseases in
adulthood [5,6]. Similarly people born preterm at very low birth
weight (VLBW, birth weight #1500 g) encounter risks for late-
onset chronic diseases [7–12]. For instance, in comparison to their
non-low-birth-weight term-born peers, VLBW subjects have
higher blood pressure [7–10] as well as impaired glucose
regulation [11,12].
Individuals born at term with a low birth weight, exposed to
famine in utero or born preterm at VLBW all share a period of poor
nutrition and growth early in life [13–15]. In the Dutch famine
studies, early caloric deprivation has been shown to be associated
with aberrant methylation at the Insulin-like growth factor-2
(IGF2) gene [16,17], which is an imprinted gene that functions as
part of the anabolic growth hormone/insulin-like growth factor
endocrine axis regulating growth. Imprinted genes are epigenet-
ically labile to early environmental influences [18] and modest
methylation shifts in their functional/regulatory regions are
associated with changes in gene expression. IGF2 is particularly
critical for growth in fetal life and plays a role in fetal growth
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restriction [19]. Whether a change in IGF2 methylation results in
enhanced incidence of chronic diseases in the Dutch famine study
population is presently unknown. However, evidence for its role as
a link between early conditions and later adult disease risk comes
from several other studies reporting associations between methyl-
ation shifts at IGF2 differentially methylated regions (DMRs) and
increased susceptibility to e.g. malignancies, as well as obesity [20].
Variation in IGF2 methylation could potentially serve as a
mediator between adult cardiovascular disease (CVD) risk and
preterm birth at VLBW.
In this study we investigated the level of IGF2 (IGF2/H19 locus)
methylation in a population of young adults born preterm at
VLBW, in whom we previously have reported elevated levels of
CVD risk factors – higher blood pressure and impaired glucose
regulation [10,12] – in comparison to their non-low-birth-weight
term-born controls. We chose to study hierarchically regulated
IGF2 DMRs through which imprinting of the IGF2 gene is
maintained. The first DMR we chose was the IGF2 antisense
transcript (IGF2AS) amplicon, also known as IGF2 DMR0 [21], in
which both gain and loss of methylation have been reported under
different conditions [16,17]. The other amplicon we chose to study
was IGF2-DMR2, overlapping the last exon of IGF2 (IGF2_05)
[22].
Subjects
The participants of this study come from The Helsinki Study of
Very Low Birth Weight Adults, which is a longitudinal follow-up
cohort of subjects born preterm at VLBW between 1978 and 1985
and treated in the Neonatal Intensive Care Unit of Children’s
Hospital of Helsinki University Central Hospital. Of the original
cohort, 255 VLBW subjects had survived from the intensive care
period and resided in the greater Helsinki area at the time of
invitation for follow-up. These subjects were invited to participate
in the study together with a sex-, age-, and birth hospital -matched
comparison group of 314 term-born subjects who were not small
for gestational age (SGA), i.e. whose birth weight was more than –
2 SD, based on Finnish growth standards [23]. Clinical visits of the
study participants as well as non-participant analysis are explained
in more detail elsewhere [10,12,24]. Altogether, 165 (65%) VLBW
and 172 (55%) control subjects participated in a clinical
examination in their early adulthood, at age 18 to 27 years. The
examination included, e.g., height and weight measurement based
on which body mass index (BMI) was calculated (weight in
kilograms divided by height in meters squared), and a 2-hour oral
glucose tolerance test. The subjects also completed detailed
questionnaires that covered their medical history, lifestyle factors,
and familial history of disease. Furthermore, blood samples were
drawn for epigenetic analyses (IGF2 methylation fraction mea-
surement). These samples were taken in a fasting state and blood
was stored as EDTA blood in a freezer (–20uC). For eight VLBW
and 11 control subjects the IGF2 methylation fraction data did not
pass quality control. We obtained reliable methylation fractions for
158 VLBW and 161 controls. For 127 VLBWs and 146 controls,
we also carried out dual-energy x-ray absorptiometry (DXA,
Discovery A, Hologic) to measure body composition.
This study was performed according to the declaration of
Helsinki. The study protocol was approved by the Ethics
committee of the Helsinki and Uusimaa Hospital District, Finland.
Written informed consent was obtained from each participant.
Methods
Assessment of methylation fractions
In the two DMRs, IGF2AS and IGF2_05, we measured the
methylation level of CpG units (i.e. fragments containing one or
more CpG sites) – six units for IGF2AS and seven units for
IGF2_05 – using Sequenom EpiTYPER (Sequenom, San Diego,
CA, USA). A fragment is produced from a PCR amplicon,
designed to contain at least 4 analyzable CpGs, which is initially
amplified from bisulfite treated DNA. The PCR amplicon is
subsequently transcribed in vitro and fragmented by RNAase to
produce smaller fragments where the cytosines of unmethylated
CpGs are present as adenosines and of methylated CpGs as
guanines. These fragments differ in mass which the EpiTYPER
software identifies. Genomic DNA was extracted from whole
peripheral EDTA blood by using QIAamp DNA Blood Maxi Kit
(QiagenH); 500 ng of DNA was then bisulfite-treated using the EZ
DNA Methylation Kit (Zymo Research Corporation, Irvine, CA,
USA) according to manufacturer’s instructions. Bisulfite treatment
and further sample processing was carried out at the Mutation
Analysis Facility, Karolinska Institutet, Sweden. Primers (Table 1)
were designed and validated using the EpiDesigner web resource
and the RseqMeth and MassArray packages in R. Two IGF2AS
CpG units with single nucleotide polymorphisms were excluded
from the analysis. One IGF2_05 CpG unit was excluded from the
analysis because of unreliable data indicated by low peaks and low
signal-to-noise ratios. Thus, we finally examined four IGF2AS and
six IGF2_05 CpG units in this study. Quality control of the data
was performed using EpiTYPER and MassArray R-script
software. Assessment of primer-dimer formation and bisulfite
conversion efficiency was made with MassArray R-script and
indicated overall good quality data. Samples with low signal, low
signal-to-noise ratio and low probability of accurate data signaled
by EpiTYPER software were eliminated. All samples were
measured in duplicate. Samples with a duplicate difference of
greater than 20% in methylation level were considered unreliable
and excluded from the analysis. Altogether seven measurements
were excluded. We used means of each duplicate as the
methylation level of that CpG unit in the analyses.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics
19.0 (Chicago, IL). To compare the baseline characteristics we
used the t test for continuous and the x2 test for categorical
variables.
To compare the methylation fraction at each IGF2AS and
IGF2_05 CpG units, we used linear regression analysis with
Bonferroni correction for multiple comparisons. We adjusted for
covariates in different models; for plate number (dummy-coded),
sex, and age in model 1, and for plate number, sex, age, height,
BMI, mother’s smoking during pregnancy [25], mother’s age at
birth, father’s age at birth, mother’s BMI before pregnancy [26],
and highest educational attainment of either parent in model 2
(full adjustment). In an additional model we also adjusted for folic
acid use of the subject [27]. Furthermore, in a subgroup with
available data we adjusted for lean body mass instead of height
and BMI.
Some of the VLBW subjects’ birth weight was equal to or less
than 1500 g (inclusion criterion) because of being just born
remarkably early, but appropriate for gestational age (AGA; birth
weight $ –2SD) [23]. Other VLBW subjects were born SGA with
less prematurity and had a birth weight of #1500 g caused by
poor intrauterine growth. We thus also examined the methylation
fractions between AGA and SGA VLBW subjects.
IGF2 Methylation in Subjects Born Preterm
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Results
Characteristics of the study participants are presented in Table
2. The VLBW participants were born at the mean gestational
week of 29.2 weeks (SD 2.2 weeks), and controls at 40.1 weeks (SD
1.2 weeks). Mean birth weight of the VLBW subjects was 1117 g
(SD 220 g), and of the controls 3602 g (SD 478 g). Of the VLBW
subjects, 53 (34%) were born SGA.
Table 3 shows the average methylation percent (%) and
standard deviations (SDs) at each CpG unit of the IGF2AS and
IGF2_05 DMR amplicons in VLBW and in control subjects, as
well as the numbers of measurements that were considered
reliable.
Table 1. IGF2AS and IGF2_05 amplicons.
Amplicon Primers
Amplicon
length
Coordinates in build
GRCh37/hg19
Coordinates in build
NCBI36/hg18
IGF2AS F:aggaagagTGGATAGGAGATTGAGGAGAAA 338 chr11:2169459-2169796 chr11:2126035-2126372
R:cagtaatacgactcactatagggagaaggctAAACCCCAACAAAAACCACT
IGF2_05 F:aggaagagagGAAGGGGTTGGTTAGTAGGTGTTTGT 276 chr11:2154463-2154738 chr11:2111039-2111314
R:agtaatacgactcactatagggagaaggctCCTAAACCCCTTTCCCACTCTCTAA
doi:10.1371/journal.pone.0067379.t001
Table 2. Characteristics of the study participants.
Characteristic VLBW (n=158) Controls (n=161) P a
Missing values (VLBW/
controls)
Women, n (%) 91 (58) 96 (60) 0.9 0/0
Men, n (%) 67 (42) 65 (40) 0.8 0/0
Birth
Gestational age, mean (SD), wk 29.2 (2.2) 40.1 (1.2) ,0.0001 0/0
Birth weight, mean (SD), g 1117 (220) 3602 (478) ,0.0001 0/0
Birth weight SDS, mean (SD), SDS –1.29 (1.53) 0.06 (1.04) ,0.0001 0/0
SGA, n (%) 53 (34) 0 0/0
Parental
Mother’s age 29.8 (4.8) 29.9 (5.1) 0.1 0/1
Father’s age 31.6 (5.6) 32.0 (6.0) 0.4 1/3
Mother’s BMI before pregnancy 22.2 (3.7) 22.3 (3.5) 0.2 27/3
Mother’s smoking during pregnancy 29 (18) 26 (16) 0.7 0/1
Highest education of either parent, n (%) 2/1
Elementary 16 (10) 9 (6) 0.2
High school 34 (22) 28 (17) 0.4
Intermediate 64 (41) 53 (33) 0.3
University 42 (27) 70 (43) 0.03
Current
Age, mean (SD), y 22.4 (2.1) 22.5 (2.2) 0.1 0/0
Height, mean (SD), cm
Women 162.0 (7.8) 167.4 (6.8) ,0.0001 0/0
Men 174.2 (7.6) 180.5 (6.5) ,0.0001 0/0
BMI, mean (SD), kg/m2
Women 22.1 (3.8) 22.8 (3.6) 0.2 0/0
Men 22.0 (3.7) 23.3 (3.3) 0.03 0/0
Lean body mass, mean (SD), kg
Women 38.9 (5.7) 43.0 (5.5) ,0.0001 5/19
Men 53.4 (8.1) 61.6 (8.0) ,0.0001 7/15
VLBW was birth weight #1500 g; SGA was birth weight less than –2SD.
aA t test for continuous and chi square test for categorical variables.
doi:10.1371/journal.pone.0067379.t002
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Differences in IGF2 methylation between VLBW and
control subjects
Mean differences and 95% confidence intervals (CIs) in
methylation fractions at IGF2AS and IGF2_05 CpG units between
VLBW and control subjects, obtained by linear regression and full
adjustment (model 2) are presented in Table 4. P-values for model
1 as well as unadjusted P-values are also shown. Males and females
were analyzed together; sex interaction was not significant (P
values $ 0.1). We found that the methylation at all IGF2AS CpG
units tended to be lower in VLBW than in control subjects, but the
difference was significant only at IGF2AS CpG3 [–0.017 (95% CI
–0.028, –0.005), P = 0.004, full adjustment]. As there were
multiple comparisons (10 CpG units), we carried out Bonferroni
correction, in which case this difference between VLBW and term
remained significant. At IGF2_05 CpG unit methylation fractions
were similar in both groups.
Adjustment for folic acid use did not change the results (data not
shown). In a subgroup with available data on body composition
and adjustment for lean body mass instead of BMI and height,
IGF2AS CpG3’s lower methylation fraction in VLBW compared to
control subjects remained significant (P = 0.006). Other results also
remained the same. Mode of delivery was not associated with
methylation levels.
Of the covariates, age of the subject had a negative effect on
methylation at IGF2AS CpG8 [–0.003 (95% CI –0.006, –0.001),
P = 0.020], and mother’s smoking during pregnancy on IGF2_05
CpG7 [–0.019 (95% CI –0.034, –0.004), P = 0.014] and IGF2_05
CpG91011 [–0.017 (95%CI –0.032, –0.002), P = 0.031]. Other
covariates did not have statistically significant effects on methyl-
ation fr actions (Table S1).
We also tested whether adult size-related characteristics or
glucose values in the 2-hour OGTT were associated with IGF2
methylation levels. Final height or adult BMI were not associated
with methylation levels at IGF2 CpG units in our study. Neither
were methylation levels associated with 2-hour glucose levels, but
there was a statistically significant association between fasting
glucose and methylation level at IGF2_05 CpG 12 (B= 1.004,
95%CI: 0.017 to 1.992, P= 0.046) and IGF2_05 CpG 34
(B= 0.957, 95%CI: 0.012 to 1.903, P = 0.047).
Differences in IGF2 methylation between VLBW subjects
born SGA and those born AGA
In analyses within the VLBW group between the VLBW
subjects born SGA and AGA, there were no significant differences
in the methylation fractions at any IGF2AS or IGF2_05 CpG units.
(Table 5). The difference in IGF2AS CpG3 unit methylation was
similarly different between VLBW-SGA and controls [–0.020
(95% CI: –0.037, –0.003), P = 0.022], as well as between VLBW-
AGA and controls [–0.018 (95% CI: –0.031, –0.005), P = 0.007].
A history of perinatal infection, bronchopulmonary dysplasia, or
maternal preeclampsia was not associated with methylation levels.
These were also similar in VLBW subjects from multiple and those
from singleton pregnancies (data not shown). Within the VLBW
group methylation levels were not associated with birth weight or
gestational age.
Discussion
Imprinted genes are epigenetically labile to early environmental
influences [18]. These mitotically heritable marks may serve as
archives of early exposure and may offer a fascinating mechanistic
explanation to the concept of developmental origins of adult
disease. The best characterized imprinted domain is IGF2 that
plays a key role in fetal growth, and alterations of methylation are
present in fetal growth restriction [19] and in Beckwidth-
Wiedemann and Silver-Russell syndromes [28,29]. In this study,
we investigated two DMRs at the IGF2 locus in young adults born
preterm at VLBW, who have previously been shown to have
elevated levels of risk factors for CVDs in adulthood [10,12]. We
found that VLBW subjects have a significantly lower methylation
level at one IGF2AS DMR CpG than their term-born peers. The
finding survived Bonferroni correction of multiple comparisons
and was not explained by potential confounding factors.
Although VLBW birth and in utero severe caloric restriction are
not exactly similar early adverse events, our finding of 2% lower
methylation in VLBW adults parallels that in the Dutch famine
study, which showed that people who had been exposed to very
early nutritional deprivation and had later increased incidence of
chronic diseases had a 5% lower IGF2 methylation level –
measured decades after the exposure – at the same CpG sites that
Table 3. Mean (SD) methylation % at different IGF2 CpG units in VLBW and control subjects.
IGF2 CpGs VLBW (n =158) Controls (n =161) Missing values (VLBW/controls)
Mean % (SD) Mean % (SD)
IGF2AS
CpG3 55.6 (0.04) 57.4 (0.05) 1/0
CpG4 60.4 (0.07) 60.9 (0.06) 1/2
CpG67 39.9 (0.04) 40.7 (0.04) 0/2
CpG8 51.8 (0.05) 52.8 (0.04) 1/2
IGF2_05
CpG12 68.5 (0.05) 68.4 (0.05) 0/0
CpG34 67.4 (0.05) 67.1 (0.05) 0/0
CpG6 50.6 (0.04) 50.7 (0.04) 0/0
CpG7 56.3 (0.05) 56.4 (0.04) 0/1
CpG8 55.4 (0.04) 55.3 (0.04) 0/0
CpG91011 53.1 (0.05) 52.7 (0.05) 0/0
VLBW was birth weight #1500 g.
doi:10.1371/journal.pone.0067379.t003
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we measured [16]. Another evidence for epigenetic mechanisms
influencing late-onset conditions comes from another study in
which hypermethylation at some imprinted gene loci sensitive to
prenatal nutrition were associated with myocardial infarction [30].
Recent studies have shown associations between gestational age at
birth and methylation at patterns in newborns at several genes
[31,32]. We are not aware of other reports on DNA methylation
patterns in subjects born preterm at VLBW. Although one study
has reported severe hypomethylation at IGF2/H19 locus in a term
patient with birth weight less than -3SDS [33], another larger
study on subjects born SGA did not reveal an association between
IGF2 methylation levels and SGA birth [34]. Accordingly, we did
not find any difference in IGF2 methylation between those VLBW
subjects that were born SGA and those born AGA. Etiologies of
SGA births are multiple and there are potentially many different
epigenetically regulated loci [35,36], as well as non-epigenetic
factors [17] that lead to later health outcomes in these subjects.
Other perinatal characteristics, such as infection, bronchopulmo-
nary dysplasia, or preeclampsia, were unrelated to methylation
levels. However, we suppose our subject population is not large
enough to permit us to properly assess these effects. In addition, it
has only limited power to assess associations with adult phenotypic
characteristics.
It is not possible to assure here that the altered methylation in
IGF2 is not a primary defect that is responsible for the premature
birth at VLBW. If the methylation change is secondary to VLBW
birth, we can not be sure either that the 2% lower IGF2AS CpG3
methylation can have any clinical relevance. Whether such a
Table 4. Differences in methylation fractions at different IGF2 CpG units between VLBW and controls by linear regression.
Model 2 Model 1 Unadjusted
Difference between VLBW and controls (95% CI)P P P
IGF2AS
CpG3 –0.017 (–0.028, –0.005) 0.004 0.0005 0.0004
CpG4 –0.010 (–0.026, 0.007) 0.248 0.527 0.505
CpG67 –0.008 (–0.017, 0.001) 0.099 0.051 0.057
CpG8 –0.008 (–0.020, 0.004) 0.178 0.053 0.066
IGF2_05
CpG12 0.004 (–0.008, 0.017) 0.511 0.846 0.860
CpG34 0.005 (–0.008, 0.018) 0.435 0.577 0.595
CpG6 –0.002 (–0.012, 0.009) 0.776 0.708 0.733
CpG7 0.001 (–0.011, 0.012) 0.933 0.745 0.765
CpG8 0.003 (–0.008, 0.013) 0.610 0.705 0.698
CpG91011 0.008 (–0.004, 0.021) 0.174 0.446 0.422
VLBW was birth weight #1500 g.
Model 1; adjusted for plate n:o, sex, age.
Model 2; adjusted for plate n:o, sex, age, height, body mass index, mother’s smoking during pregnancy, mother’s age, father’s age, mother’s body mass index before
pregnancy, and highest education of either parent.
doi:10.1371/journal.pone.0067379.t004
Table 5. Differences in methylation fractions at different IGF2 CpG units between VLBW subjects born SGA and VLBW subjects
born AGA by linear regression.
Difference between VLBW-SGA and VLBW-AGA (95% CI) P
IGF2AS
IGF2_AS_CpG3 0.002 (–0.014, 0.019) 0.801
IGF2_AS_CpG4 0.002 (–0.022, 0.026) 0.125
IGF2_AS_CpG67 0.001 (–0.013, 0.015) 0.174
IGF2_AS_CpG8 0.001 (–0.017, 0.018) 0.953
IGF2_05
IGF2_05_CpG12 –0.009 (–0.027, 0.010) 0.354
IGF2_05_CpG34 –0.011 (–0.029, 0.008) 0.253
IGF2_05_CpG6 –0.004 (–0.020, 0.012) 0.640
IGF2_05_CpG7 –0.004 (–0.022, 0.015) 0.685
IGF2_05_CpG8 –0.009 (–0.025, 0.007) 0.268
IGF2_05_CpG91011 –0.007 (–0.025, 0.011) 0.459
VLBW was birth weight #1500 g; SGA was birth weight less than –2SD; AGA was birth weigh equal to or more than 2SD.
doi:10.1371/journal.pone.0067379.t005
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minor reduction in methylation can have functional consequence,
such as downregulation of IGF2 function, is not known. However,
methylation differences may be more significant in other tissues
than the white blood cells from whole blood samples that we
studied here [37,38]. Analysis of methylation in, e.g., fat and
muscle would give more detailed data for methylation associated
with VLBW birth, but other tissues than blood were not available
from our subjects. In addition to different tissues, methylation
levels also vary across different blood cell types [38]. Thus, the
methylation levels studied could be affected by differential cell
count in whole blood samples. Using a publicly available database
[39], we checked the methylation levels for available CpGs within
1 kb from our amplicons, and did not find major methylation
differences between blood cell types that would have affected the
interpretation of our results.
A clear advantage of this study is that the study population was
exceptionally well characterized allowing for, e.g., adjustment for
most important potential confounders that could affect IGF2
methylation levels. It has been stated that infants born to smokers
have higher methylation at the IGF2 than those born to non-
smokers [25]. Moreover, mother’s obesity before pregnancy may
influence IGF2 methylation and gene expression [26]. Although
we observed a significant effect of mother’s smoking during
pregnancy on methylation at some CpG units neither this nor any
other confounding factor explained the differences in the IGF2AS
CpG3 methylation fraction between VLBW and control subjects.
We did not adjust for mode of delivery, since the reasons for
cesarean section are different in preterm and term pregnancies. In
our study, mode of delivery was not associated with methylation
levels. In vitro fertilization has been reported to affect methylation
patterns [40], but it was not used in the 1970s. Ethnicity could also
have an influence on methylation patterns, but our study
participants were almost exclusively of Finnish origin. Folic acid
supplementation that has been suggested to increase the risk of
adult chronic diseases has been reported to be associated with
methylation levels [41]. We adjusted for folic acid use, but it did
not change the results.
A minor disadvantage in our study is the number of study
participants which was relatively small. Moreover, our study
participants may not be representative of the original VLBW
cohort, but this would only be expected to introduce bias if the
association between VLBW birth and IGF2 methylation was
different among participants and non-participants. This cannot be
excluded.
Conclusions
In conclusion, we observed a significant difference in the
methylation fraction at one IGF2AS DMR CpG site between
preterm-born VLBW young adults with elevated levels of CVD
risk factors in comparison to controls born at term. More data are
needed to indicate whether IGF2 methylation patterns can be
causal for VLBW subjects’ higher levels of risk factors of
cardiovascular disease and type 2 diabetes.
Supporting Information
Table S1 Differences in methylation fractions at differ-
ent IGF2AS and IGF2_05 CpG units between VLBW and
control subjects by linear regression, and effects of
covariates [B, 95% confidence interval (CI), and P]
adjusted for in the model.
(RTF)
Author Contributions
Conceived and designed the experiments: KW PH MM SBW JK EK.
Performed the experiments: MM SBW EK. Analyzed the data: KW MM
SBW PH JK EK. Contributed reagents/materials/analysis tools: SBW EK
JGE EK. Wrote the paper: KW MM KH-J PH JK EK SA JGE. Collected
the participants and performed the clinical studies: PH A-LJ JGE SA EK.
References
1. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ (1989) Weight in
infancy and death from ischaemic heart disease. Lancet 2:577–580.
2. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, et al. (1991) Fetal and infant
growth and impaired glucose tolerance at age 64. BMJ 303:1019–1022.
3. Rich-Edwards JW, Stampfer MJ, Manson JE, Rosner B, Hankinson SE, et al.
(1997) Birth weight and risk of cardiovascular disease in a cohort of women
followed up since 1976. BMJ 315:396–400.
4. Huxley R, Owen CG, Whincup PH, Cook DG, Rich-Edwards J, et al. (2007) Is
birth weight a risk factor for ischemic heart disease in later life? Am J Clin Nutr
85:1244–1250.
5. Roseboom TJ, Painter RC, van Abeelen AF, Veenendaal MV, de Rooij SR
(2011) Hungry in the womb: What are the consequences? Lessons from the
Dutch famine. Maturitas 70:141–145.
6. Hult M, Tornhammar P, Ueda P, Chima C, Bonamy AK, et al. (2010)
Hypertension, diabetes and overweight: looming legacies of the Biafran famine.
PLoS One 22;5:e13582.
7. Doyle LW, Faber B, Callanan C, Morley R (2003) Blood pressure in late
adolescence and very low birth weight. Pediatrics 111:252–257.
8. Jong F, Monuteaux MC, van Elburg RM, Gillman MW, Belfort MB (2012)
Systematic review and meta-analysis of preterm birth and later systolic blood
pressure. Hypertension 59:226–234.
9. Pyha¨la¨ R, Ra¨ikko¨nen K, Feldt K, Andersson S, Hovi P, et al. (2009) Blood
pressure responses to psychosocial stress in young adults with very low birth
weight: Helsinki study of very low birth weight adults. Pediatrics 123:731–734.
10. Hovi P, Andersson S, Ra¨ikko¨nen K, Strang-Karlsson S, Ja¨rvenpa¨a¨ AL, et al.
(2010) Ambulatory blood pressure in young adults with very low birth weight. J
Pediatr 156:54–59.e1.
11. Hofman PL, Regan F, Jackson WE, Jefferies C, Knight DB, et al. (2004)
Premature birth and later insulin resistance. N Engl J Med 351:2179–2186.
12. Hovi P, Andersson S, Eriksson JG, Ja¨rvenpa¨a¨ AL, Strang-Karlsson S, et al.
(2007) Glucose regulation in young adults with very low birth weight. N Engl J
Med 356:2053–2063.
13. Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG (2005) Trajectories
of growth among children who have coronary events as adults. N Engl J Med
353:1802–1809.
14. Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, e al. (2004)
Relation of serial changes in childhood body-mass index to impaired glucose
tolerance in young adulthood. N Engl J Med 350:865–875.
15. Eriksson JG, Osmond C, Kajantie E, Forsen TJ, Barker DJ (2006) Patterns of
growth among children who later develop type 2 diabetes or its risk factors.
Diabetologia 49:2853–2858.
16. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, et al. (2008) Persistent
epigenetic differences associated with prenatal exposure to famine in humans.
Proc Natl Acad Sci U S A 105:17046–17049.
17. Tobi EW, Slagboom PE, van Dongen J, Kremer D, Stein AD, et al. (2012)
Prenatal famine and genetic variation are independently and additively
associated with DNA methylation at regulatory loci within IGF2/H19. PLoS
One 7:e37933.
18. Waterland RA, Jirtle RL (2004) Early nutrition, epigenetic changes at
transposons and imprinted genes, and enhanced susceptibility to adult chronic
diseases. Nutrition 20:63–68.
19. Koukoura O, Sifakis S, Soufla G, Zaravinos A, Apostolidou S, et al. (2011) Loss
of imprinting and aberrant methylation of IGF2 in placentas from pregnancies
complicated with fetal growth restriction. Int J Mol Med 28:481–487.
20. Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease
susceptibility. Nat Rev Genet 8:253–262.
21. Heijmans BT, Kremer D, Tobi EW, Boomsma DI, Slagboom PE (2007)
Heritable rather than age-related environmental and stochastic factors dominate
variation in DNA methylation of the human IGF2/H19 locus. Hum Mol Genet
16:547–554.
22. Lopes S, Lewis A, Hajkova P, Dean W, Oswald J, et al. (2003) Epigenetic
modifications in an imprinting cluster are controlled by a hierarchy of DMRs
suggesting long-range chromatin interactions. Hum Mol Genet 12:295–305.
23. Pihkala J, Hakala T, Voutilainen P, Raivio K (1989) Characteristic of recent
fetal growth curves in finland. Duodecim 105:1540–1546.
24. Hovi P, Andersson S, Ja¨rvenpa¨a¨ AL, Eriksson JG, Strang-Karlsson S, et al.
(2009) Decreased bone mineral density in adults born with very low birth weight:
A cohort study. PLoS Med 6:e1000135.
IGF2 Methylation in Subjects Born Preterm
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e67379
25. Murphy SK, Adigun A, Huang Z, Overcash F, Wang F, et al. (2011) Gender-
specific methylation differences in relation to prenatal exposure to cigarette
smoke. Gene 494:36–43.
26. Hoyo C, Fortner K, Murtha AP, Schildkraut JM, Soubry A, et al. (2012)
Association of cord blood methylation fractions at imprinted insulin-like growth
factor 2 (IGF2), plasma IGF2, and birth weight. Cancer Causes Control 23:635–
645.
27. Anderson OS, Sant KE, Dolinoy DC (2012) Nutrition and epigenetics: an
interplay of dietary methyl donors, one-carbon metabolism and DNA
methylation. J Nutr Biochem 23:853–859.
28. Azzi S, Rossignol S, Steunou V, Sas T, Thibaud N, et al. (2009) Multilocus
methylation analysis in a large cohort of 11p15-related foetal growth disorders
(Russell Silver and Beckwith Wiedemann syndromes) reveals simultaneous loss of
methylation at paternal and maternal imprinted loci. Hum Mol Genet 18:4724–
4733.
29. Netchine I, Rossignol S, Dufourg MN, Azzi S, Rousseau A, et al. (2007) 11p15
imprinting center region 1 loss of methylation is a common and specific cause of
typical Russell-Silver syndrome: Clinical scoring system and epigenetic-
phenotypic correlations. J Clin Endocrinol Metab 92:3148–3154.
30. Talens RP, Jukema JW, Trompet S, Kremer D, Westendorp RG, et al. (2011)
Hypermethylation at loci sensitive to the prenatal environment is associated with
increased incidence of myocardial infarction. Int J Epidemiol 41:106–15.
31. Lee H, Jaffe AE, Feinberg JI, Tryggvadottir R, Brown S, et al. (2012) DNA
methylation shows genome-wide association of NFIX, RAPGEF2 and MSRB3
with gestational age at birth. Int J Epidemiol 41:188–99.
32. Schroeder JW, Conneely KN, Cubells JC, Kilaru V, Newport DJ, et al. (2011)
Neonatal DNA methylation patterns associate with gestational age. Epigenetics
6:1498–504.
33. Murphy R, Iba´n˜ez L, Hattersley A, Tost J (2012) IGF2/H19 hypomethylation in
a patient with very low birthweight, preocious pubarche and insulin resistance.
BMC Med Genet 30;13:42.
34. Tobi EW, Heijmans BT, Kremer D, Putter H, Delemarre-van de Waal HA, et
al. (2011) DNA methylation of IGF2, GNASAS, INSIGF and LEP and being
born small for gestational age. Epigenetics 6:171–176.
35. Lumey LH, Terry MB, Delgado-Cruzata L, Liao Y, Wang Q, et al. (2012) Adult
global DNA methylation in relation to pre-natal nutrition. Int J Epidemiol
41:116–123.
36. Turan N, Ghalwash MF, Katari S, Coutifaris C, Obradovic Z, et al. (2012)
DNA methylation differences at growth related genes correlate with birth
weight: A molecular signature linked to developmental origins of adult disease?
BMC Med Genomics 5:10.
37. Hoyo C, Murphy SK, Jirtle RL (2009) Imprint regulatory elements as epigenetic
biosensors of exposure in epidemiological studies. J Epidemiol Community
Health 63:683–684.
38. Reinius LE, Acevedo N, Joerink M (2012) Differential DNA methylation in
purified human blood cells: Implications for cell lineage and studies on disease
susceptibility. 7:e41361.
39. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahle´n SE, et al. (2012)
Differential DNA methylation in purified human blood cells: implications for cell
lineage and studies on disease susceptibility. Available: http://publications.
scilifelab.se/kere_j/methylation.
40. Turan N, Katari S, Gerson LF, Chalian R, Foster MW, et al. (2010) Inter- and
intra-individual variation in allele-specific DNA methylation and gene
expression in children conceived using assisted reproductive technology. PLoS
Genet 6:e1001033.
41. Hoyo C, Murtha AP, Schildkraut JM, Jirtle RL, Demark-Wahnefried W, et al.
(2011) Methylation variation at IGF2 differentially methylated regions and
maternal folic acid use before and during pregnancy. Epigenetics 6:928–936.
IGF2 Methylation in Subjects Born Preterm
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e67379
